Generic Orbactiv Availability
ORBACTIV (oritavancin diphosphate - powder;iv (infusion))
Manufacturer: THE MEDICINES CO
Approval date: August 6, 2014
Strength(s): EQ 400MG BASE/VIAL [RLD]
Has a generic version of Orbactiv been approved?
No. There is currently no therapeutically equivalent version of Orbactiv available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orbactiv. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Glycopeptide antibiotic derivatives
Issued: November 24, 1998
Inventor(s): Cooper; Robin D. G. & Huff; Bret E. & Nicas; Thalia I. & Quatroche; John T. & Rodriguez; Michael J. & Snyder; Nancy J. & Staszak; Michael A. & Thompson; Richard C. & Wilkie; Stephen C. & Zweifel; Mark J.
Assignee(s): Eli Lilly and Company
The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.Patent expiration dates:
- November 24, 2017✓✓✓
- November 24, 2017
Reductive alkylation of glycopeptide antibiotics
Issued: December 7, 1999
Inventor(s): Berglund; Richard Alan & Lockwood; Nancy Anne & Magadanz; Howard Eugene & Zheng; Hua
Assignee(s): Eli Lilly and Company
This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics. The improvement residing in providing a source of copper which results in the initial production of a copper complex of the glycopeptide antibiotic. Reductive alkylation of this complex favors regioselective alkylation and increased yields. Copper complexes of the glycopeptide antibiotic starting materials and of the alkylated products are also part of the invention.Patent expiration dates:
- November 12, 2017✓
- November 12, 2017
Methods of treatment using single doses of oritavancin
Issued: April 16, 2013
Assignee(s): The Medicines Company
Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.Patent expiration dates:
- August 29, 2029✓
- August 29, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- August 6, 2019 - NEW CHEMICAL ENTITY
- August 6, 2024 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Orbactiv (oritavancin)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews – Add your own review/rating
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|